Sage Therapeutics (SAGE) News Today $7.32 +0.17 (+2.31%) As of 01:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period HC Wainwright Lifts Earnings Estimates for Sage TherapeuticsFebruary 17, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Outlook for SAGE EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued to investors on Wednesday, February 12th. HC Wainwright analyst D. Tsao now expects that the bioFebruary 17, 2025 | marketbeat.comShort Interest in Sage Therapeutics, Inc. (NASDAQ:SAGE) Decreases By 32.0%Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,170,000 shares, a decline of 32.0% from the January 15th total of 6,130,000 shares. Approximately 7.8% of the company's shares are short sold. Based on an average daily volume of 1,710,000 shares, the days-to-cover ratio is currently 2.4 days.February 15, 2025 | marketbeat.comEquities Analysts Set Expectations for SAGE Q3 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Sage Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical companyFebruary 15, 2025 | marketbeat.comResearch Analysts Set Expectations for SAGE Q3 EarningsFebruary 15, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for SAGE Q1 Earnings?February 15, 2025 | americanbankingnews.comCanaccord Genuity Group Has Lowered Expectations for Sage Therapeutics (NASDAQ:SAGE) Stock PriceFebruary 14, 2025 | americanbankingnews.comSAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and GrowthFebruary 13, 2025 | msn.comSage Therapeutics price target lowered to $12 from $14 at ScotiabankFebruary 13, 2025 | finance.yahoo.comBrokers Offer Predictions for SAGE Q1 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for Sage Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will earn ($1.03) per shFebruary 13, 2025 | marketbeat.comSage stock price target cut to $12 by H.C. WainwrightFebruary 12, 2025 | msn.comQ4 2024 SAGE Therapeutics Inc Earnings CallFebruary 12, 2025 | uk.finance.yahoo.comA Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 AnalystsFebruary 12, 2025 | benzinga.comCanaccord cuts Sage Therapeutics price target to $8, holds ratingFebruary 12, 2025 | msn.comSage Therapeutics (NASDAQ:SAGE) Price Target Lowered to $12.00 at ScotiabankScotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research report on Wednesday.February 12, 2025 | marketbeat.comWedbush Reaffirms Neutral Rating for Sage Therapeutics (NASDAQ:SAGE)Wedbush reissued a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday.February 12, 2025 | marketbeat.comCanaccord Genuity Group Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $8.00Canaccord Genuity Group reduced their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday.February 12, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Receives Hold Rating from Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday.February 12, 2025 | marketbeat.comSage Therapeutics' (SAGE) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday.February 12, 2025 | marketbeat.comSage brushes off 'strategic alternatives' questions during earnings callFebruary 12, 2025 | bizjournals.comSage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | seekingalpha.comSage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.February 11, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Announces Earnings Results, Misses Estimates By $0.02 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.February 11, 2025 | marketbeat.comSage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business UpdatesFebruary 11, 2025 | businesswire.comSage Therapeutics (SAGE) Projected to Post Quarterly Earnings on TuesdaySage Therapeutics (NASDAQ:SAGE) will be releasing earnings after the market closes on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660037)February 9, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by BrokeragesShares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommFebruary 6, 2025 | marketbeat.comSage Therapeutics (SAGE) Projected to Post Earnings on TuesdaySage Therapeutics (NASDAQ:SAGE) will be releasing earnings after the market closes on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660037)February 4, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Sees Significant Increase in Short InterestSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 6,130,000 shares, a growth of 26.9% from the December 31st total of 4,830,000 shares. Approximately 11.7% of the shares of the stock are sold short. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is currently 3.9 days.February 3, 2025 | marketbeat.comFY2025 Earnings Estimate for SAGE Issued By Leerink PartnrsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Sage Therapeutics in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biophJanuary 31, 2025 | marketbeat.comThe Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero TherapeuticsJanuary 30, 2025 | finance.yahoo.comSAGE Therapeutics (SAGE) Gets a Hold from Mizuho SecuritiesJanuary 30, 2025 | markets.businessinsider.comSage Therapeutics price target raised to $9 from $6 at MizuhoJanuary 30, 2025 | markets.businessinsider.comMizuho raises Sage Therapeutics target to $9 on Biogen bidJanuary 30, 2025 | msn.comSAGE Stock Up on Rejecting BIIB’s ProposalJanuary 29, 2025 | finance.yahoo.comSage rejects Biogen’s $469m takeover bidJanuary 29, 2025 | msn.comSage Therapeutics shares rise amid strategic reviewJanuary 27, 2025 | au.investing.comSage rejects Biogen's takeover offer, to explore strategic alternativesJanuary 27, 2025 | finance.yahoo.comSage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition ProposalJanuary 27, 2025 | finance.yahoo.comSage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition ProposalJanuary 27, 2025 | businesswire.comFY2024 EPS Estimates for Sage Therapeutics Lifted by WedbushSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Wedbush lifted their FY2024 earnings estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceuticalJanuary 27, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Assenagon Asset Management S.A. lessened its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 35.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 120,723 sharJanuary 25, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 87.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 150,823 shares of the biopharmaceutical company's stock after selling 1,049,152 shares duJanuary 25, 2025 | marketbeat.comSionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis TreatmentsJanuary 24, 2025 | seekingalpha.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmJanuary 24, 2025 | gurufocus.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmJanuary 24, 2025 | investing.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmJanuary 24, 2025 | globenewswire.comBrokers Issue Forecasts for SAGE FY2029 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Sage Therapeutics in a report released on Thursday, January 23rd. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will earn $0.35 per shJanuary 24, 2025 | marketbeat.comRBC Capital Remains a Hold on SAGE Therapeutics (SAGE)January 23, 2025 | markets.businessinsider.comTD Cowen Keeps Their Hold Rating on SAGE Therapeutics (SAGE)January 22, 2025 | markets.businessinsider.comScotiabank Remains a Buy on SAGE Therapeutics (SAGE)January 21, 2025 | markets.businessinsider.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.810.60▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼139▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vera Therapeutics News Today Iovance Biotherapeutics News Today Praxis Precision Medicines News Today Galapagos News Today Wave Life Sciences News Today Apogee Therapeutics News Today Evotec News Today Disc Medicine News Today Arcutis Biotherapeutics News Today Amphastar Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts